Synmosa Biopharma Corporation (4114.TWO)

39.10 +0.35 (+0.90%) At close: 01:30PM CST

Synmosa Biopharma Corporation

No. 396, Neihu Road
11th Floor Section 1 Neihu District
Taipei 114
Taiwan
886 2 8797 7100
https://www.synmosa.com.tw

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chih-Hui Lin	Chairman, GM, Managerial Officer & President	4.71M	N/A	1983
Mr. Hong-Qin Bai	Senior VP & Finance Officer	3.5M	N/A	N/A
Ms. Jia-Xin Zhang	Senior Vice President	3.02M	N/A	N/A
Mr. Sheng-Ren Yang	Senior Vice President	3.14M	N/A	N/A
Mr. Hung-Chin Pai	Senior VP & Accounting Officer	N/A	N/A	N/A
Mr. Zen Young	Vice President of Sales - HP, Marketing & Medical	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. It also offers contract manufacturing services. In addition, it exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei, Taiwan.

Corporate governance

Synmosa Biopharma Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.